Novo Nordisk has ended its collaboration with Hims & Hers Health for its Wegovy weight-loss blockbuster treatment roughly a month after it began over concerns about what it said was illegal mass ...

Mounjaro offers up to 20% weight loss – but it’s not for everyone. Learn about eligibility, alternatives and why long-term ...

With weight-loss injections like Semaglutide gaining popularity, experts warn they’re not a one-size-fits-all fix. We got in touch with an expert who explains why long-term success lies in combining ...

THEY are arguably the biggest medical breakthrough of recent times. And from Monday, so-called ‘fat jabs’ will be made ...

Gone are the days of battling obesity with a limited toolbox. With more weight loss supplements and drugs on the market than ever before, deciding which medication is right for you isn' ...

Ozempic and other semaglutide medications have been working wonders in terms of shedding pounds for many people, but a new ...

GLP-1 drugs are revolutionizing the treatment of obesity and diabetes. Here's what to know about investing in GLP-1 stocks.

A new obesity drug combining four hormones may outperform Wegovy and Mounjaro. Learn what it means for health, science, and investors.

GLP-1 drugs like Ozempic help with weight loss, but how do they stack up against bariatric surgery? A new study breaks it ...

At the same time, and likely because of this, data shows that demand for bariatric surgery has plunged, dropping nearly 26 ...

This study adds to the growing evidence that while GLP-1 medications can be helpful for some patients, bariatric surgery remains the most powerful option for substantial and lasting weight ...